A structured overview of all scientific and operational activities carried out from October 2025 to July 2027, organized across interconnected Work Packages (WP1-WP4)
WP1
Main Activities
A1.1 — Selection of TNBC tissue samples
A1.2 — Laser microdissection
A1.3 — Sample preparation for LC–MS
A1.4 — Mass spectrometry proteomic analysis
A1.5 — Identification of biomarkers & subtype profiling
Expected Outputs
Proteomic dataset from ≥30 TNBC samples
Set of candidate biomarkers
Tumor subtype classification based on proteome signatures
Milestones
M1.1 — Completion of sample selection
M1.2 — Validation of proteomic dataset
WP2
Main Activities
AA2.1 — Cell line sourcing and authentication
A2.2 — Proteomic profiling
A2.3 — Comparative analysis vs tumor proteomes
A2.4 — Selection of representative cell lines
Expected Outputs
Validated TNBC cell lines mapped to clinical profiles
Molecular subtype alignment for downstream assays
Milestones
M2.1 — Completion of cell line proteomics
M2.2 — Finalizing cell line selection
WP3
Main Activities
A3.1 — Drug screening (single/dual/triple combinations)
A3.2 — Viability & functional assays
A3.3 — Morphological imaging
A3.4 — MOA proteomics
Expected Outputs
Drug ranking report
Pathway-level mechanistic analysis
Phenotype response dataset
Milestones
M3.1 — Completion of drug screening
M3.2 — Delivery of top candidate list
WP4
Main Activities
A4.1 — Optimization of TNBC mouse
A4.2 — In vivo drug testing
A4.3 — IVIS imaging workflow
A4.4 — IHC + proteomics evaluation of treated tumors
Expected Outputs
Preclinical validation of top therapy candidates
Imaging-based tumor burden trajectories
In vivo biomarker signatures
Milestones
M4.1 — Mouse model established
M4.2 — In vivo experiments completed
M4.3 — Final dataset delivered
PROGRESS
Project website launched
Kick-off meeting organized between Romanian and Moldovan teams
TNBC sample selection strategy defined
Cell line panel shortlisted for WP2
Ethical approvals and biospecimen documentation in progress